Home › Keratoconus › NCT07629557

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

Single-arm, Multi-center Study to Evaluate the Safety and Feasibility of Bilateral Epithelium-on Corneal Collagen Cross-linking With Epioxa™ HD/Epioxa™ and UV-A Irradiation Using the O2n™ System and Supplemental Oxygen Using the Boost Goggles® in Subjects With Keratoconus

Who can join

Ages 13 and older · All sexes

Inclusion Criteria:

* Provide written informed consent
* Willing and able to comply with study instructions and follow-up visits
* Diagnosis of keratoconus in each eye

Exclusion Criteria:

* Known allergy or sensitivity to study medications
* History of corneal disease
* Prior corneal cross-linking in either eye
* Pregnant, nursing, or planning pregnancy during the study period
* Participated in other investigational drug or device trial within 30 days of the study

About the study

Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.

What is being tested

• Riboflavin Ophthalmic Solutions (drug)
• UV-A Irradiation System (device)

Sponsor: Glaukos Corporation · Participants: 15 · Started: May 11, 2026

Contact the study team

• Study Director · Phone: 949-739-8749

Official record on ClinicalTrials.gov — NCT07629557

Locations in the U.S.

Conditions

• Keratoconus

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.